Cargando…

Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight

BACKGROUND: Metastatic head and neck squamous cell carcinoma (HNSCC) carries a very poor prognosis. A better understanding of the molecular driver of the disease and the identification of biomarkers of response remain paramount for an effective personalized therapy. CASE REPORT: We report an origina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peddi, Prakash, Paryani, Bhavna, Takalkar, Amol, Bundrick, Paige, Ponugupati, John, Nair, Binu, El-Osta, Hazem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755421/ https://www.ncbi.nlm.nih.gov/pubmed/26929641 http://dx.doi.org/10.2147/OTT.S99667

Ejemplares similares

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
por: Peddi, Prakash, et al.
Publicado: (2015)

Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review
por: Sommerhalder, David, et al.
Publicado: (2017)

Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature
por: Bloomer, Chance H., et al.
Publicado: (2023)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Efficacy of Liver Chemoembolization after Prior Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer
por: Szemitko, Marcin, et al.
Publicado: (2023)

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
por: El-Osta, Hazem, et al.
Publicado: (2016)

Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report
por: MEKATA, EIJI, et al.
Publicado: (2013)

Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam
por: Peddi, Prakash, et al.
Publicado: (2016)

Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone
por: Takalkar, Amol, et al.
Publicado: (2014)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
por: Yazdi, Mohammad Hossein, et al.
Publicado: (2015)

Cetuximab-Induced Small Intestine Stricture in Metastatic Squamous Cell Carcinoma of the Oral Cavity
por: Eisa, Mohamed, et al.
Publicado: (2022)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Candida albicans oropharyngeal infection is an exception to iron-based nutritional immunity
por: Solis, Norma V., et al.
Publicado: (2023)

Candida albicans Oropharyngeal Infection Is an Exception to Iron-Based Nutritional Immunity
por: Solis, Norma V., et al.
Publicado: (2023)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab
por: Sun, Chaonan, et al.
Publicado: (2017)

Comparing cisplatin-Chemoradiotherapy to Cetuximab-radiotherapy in HPV(+) “low-risk” locally advanced oropharyngeal squamous cell carcinoma: lessons from De-escalate study
por: Economopoulou, Panagiota, et al.
Publicado: (2019)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis
por: Vermeer, Daniel W., et al.
Publicado: (2016)

Emerging insights into recurrent and metastatic human papillomavirus‐related oropharyngeal squamous cell carcinoma
por: Faraji, Farhoud, et al.
Publicado: (2017)

Exceptional Eight-year Response to Stereotactic Radiosurgery Monotherapy for Multiple Brain Metastases
por: Kalash, Ronny, et al.
Publicado: (2017)

Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy
por: Tanaka, Tomohiro, et al.
Publicado: (2023)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
por: Chen, Tien-Hua, et al.
Publicado: (2022)

Carboplatin-Pemetrexed in Treatment of Patients with Recurrent/Metastatic Cancers of the Head and Neck; Superior Outcomes in Oropharyngeal Primaries
por: Malhotra, Binu, et al.
Publicado: (2015)

Mutation patterns in recurrent and/or metastatic oropharyngeal squamous cell carcinomas in relation to human papillomavirus status
por: Reder, Henrike, et al.
Publicado: (2021)

Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas
por: Sadeghirad, Habib, et al.
Publicado: (2022)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
por: El-Osta, Hazem, et al.
Publicado: (2015)

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
por: Price, Timothy, et al.
Publicado: (2020)

DEK associates with tumor stage and outcome in HPV16 positive oropharyngeal squamous cell carcinoma
por: Smith, Eric A., et al.
Publicado: (2017)

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck(†)
por: Seiwert, T. Y., et al.
Publicado: (2014)

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial
por: Lu, Zhihao, et al.
Publicado: (2022)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Chauffert, Bruno, et al.
Publicado: (2023)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma
por: Janmaat, Vincent T., et al.
Publicado: (2016)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4qgj2409a3lukfb0lavildqj0d